Published in Leukemia on November 21, 2012
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma (2014) 1.48
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia (2013) 1.39
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer (2016) 1.39
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia (2014) 0.99
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood (2014) 0.91
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Int J Mol Sci (2015) 0.90
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia (2013) 0.87
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget (2015) 0.85
Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget (2015) 0.81
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J (2016) 0.80
Localized Relapse of Primary Plasma Cell Leukaemia in the Central Nervous System. Case Rep Hematol (2015) 0.79
Plasma Cell Leukemia Presenting as a Chest Wall Mass: A Case Report. Case Rep Oncol (2016) 0.78
Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplant (2015) 0.78
A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Haematologica (2014) 0.77
Primary plasma cell leukaemia with unusual presentations: a case series. Indian J Hematol Blood Transfus (2014) 0.77
Plasma cell leukemia: A case series from South India with emphasis on rarer variants. Indian J Med Paediatr Oncol (2014) 0.77
Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma. Medicine (Baltimore) (2015) 0.76
An Unfortunate Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Change (POEMS). Cureus (2017) 0.75
Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature. Blood Res (2016) 0.75
Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. Hematol Rep (2016) 0.75
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J (2016) 0.75
Radiographic features of plasma cell leukemia in the maxilla: A case report. Imaging Sci Dent (2016) 0.75
Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry. Rev Bras Hematol Hemoter (2016) 0.75
Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient. Hematol Rep (2017) 0.75
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc (2017) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Multiple myeloma: review of 869 cases. Mayo Clin Proc (1975) 4.59
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood (1999) 3.44
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma (2007) 2.41
Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control (2007) 2.09
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat (2001) 1.80
Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am (1999) 1.75
Plasma cell leukemia. Report on 17 cases. Arch Intern Med (1974) 1.66
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 1.66
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood (2002) 1.63
Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica (2006) 1.62
Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol (1991) 1.59
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Plasma cell leukemia: an evaluation of response to therapy. Am J Med (1987) 1.51
CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group. Br J Haematol (2010) 1.47
How I treat plasma cell leukemia. Blood (2012) 1.46
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer (2007) 1.27
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am (2007) 1.26
Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica (2010) 1.26
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia (1998) 1.22
Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis (2009) 1.18
Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol (2005) 1.16
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia (2012) 1.11
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol (2003) 1.10
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol (2011) 1.07
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol (2005) 1.05
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer (1992) 1.04
Plasma cell leukemia. Semin Hematol (1987) 1.04
Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer (2009) 1.03
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res (2008) 1.03
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia (2011) 1.02
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol (2011) 1.02
Primary plasma cell leukaemia: a report of 18 cases. Leuk Res (2001) 1.00
Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer (2009) 1.00
Amplification of the c-myc oncogene in human plasma-cell leukemia. Int J Cancer (1985) 0.99
Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis (2007) 0.97
Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol (2007) 0.96
Polyclonal reactive peripheral blood plasmacytosis mimicking plasma cell leukemia in a patient with Staphylococcal sepsis. Leuk Lymphoma (2003) 0.95
Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res (2008) 0.94
Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma (2008) 0.93
Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer (2005) 0.93
Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk (2011) 0.92
Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma (2007) 0.91
Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia (2001) 0.90
Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res (1997) 0.90
Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res (2008) 0.88
Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leuk Lymphoma (1996) 0.88
Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma (2002) 0.87
Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol (2006) 0.87
Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res (2008) 0.86
Plasma cell leukaemia. Diagnostic problems in our experience with 11 cases. Acta Haematol (1980) 0.86
Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res (2011) 0.86
p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J (2001) 0.86
Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications. Leuk Lymphoma (2007) 0.84
Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol (2009) 0.84
Plasma cell leukemia (PCL): A report on 15 patients. Blood (1978) 0.84
A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol (2009) 0.83
Erythrophagocytosis in a case of plasma cell leukemia. Blood (1953) 0.83
Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol (2002) 0.83
Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol (2007) 0.81
CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression. Br J Haematol (2002) 0.80
Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma (1999) 0.80
[Primary plasma cell leukemia (IgD-lambda) with hyperammonemia]. Nihon Naika Gakkai Zasshi (2004) 0.78
Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol (2010) 0.78
CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases. Br J Haematol (2004) 0.78
Highly complex chromosomal abnormalities in plasma cell leukemia as detected by FISH technique. Leukemia (1997) 0.77
Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature. Clin Lymphoma Myeloma (2008) 0.77
Up-regulation of IL-6-receptors by IL-3 on a plasma cell leukaemia cell line which proliferates dependently on both IL-3 and IL-6. Br J Haematol (1993) 0.77
Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukemia. N Engl J Med (2003) 0.77
Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report. Leuk Res (2009) 0.77
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. Am J Hematol (2009) 0.77
First case of plasma-cell leukaemia co-existing with human immunodeficiency virus infection. Leukemia (1998) 0.76
Plasma-cell leukemia and human herpesvirus 8 infection. Leukemia (2004) 0.76
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res (1981) 15.12
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med (1995) 6.52
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Multiple myeloma: review of 869 cases. Mayo Clin Proc (1975) 4.59
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
The calmodulin-sensitive adenylate cyclase of Bordetella pertussis: cloning and expression in Escherichia coli. Mol Microbiol (1988) 4.15
Single neurons in prefrontal cortex encode abstract rules. Nature (2001) 4.05
Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J Virol (1990) 4.01
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood (1999) 3.44
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med (1996) 3.41
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Amyloidosis: review of 236 cases. Medicine (Baltimore) (1975) 3.39
Clinical outcome of extramedullary plasmacytoma. Haematologica (2000) 3.27
Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc (1983) 3.22
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med (1978) 3.08
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Borna disease: a persistent virus infection of the central nervous system. Prog Med Virol (1988) 2.83
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood (1984) 2.74
Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A (1994) 2.74
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med (1978) 2.70
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med (1970) 2.61
Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol (1991) 2.59
Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol (1996) 2.48
Viridans streptococcal bacteraemia in patients with neutropenia. Lancet (1995) 2.46
Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A (1992) 2.44
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene (2001) 2.39
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion (1996) 2.37
Repetitive sequences in complete and defective genomes of Herpesvirus saimiri. J Virol (1975) 2.36
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science (1985) 2.33
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol (2010) 2.32
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Borna disease virus genome transcribed and expressed in psychiatric patients. Nat Med (1995) 2.30